

Plinio Cirillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1349898/publications.pdf>

Version: 2024-02-01

142
papers

3,796
citations

117571

34
h-index

143943

57
g-index

145
all docs

145
docs citations

145
times ranked

4489
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Inhibition with Ticagrelor 60Âmg Versus 90Âmg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 1031-1038.	1.3	3
2	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 739-749.	1.0	5
3	Prognostic value of 12-leads admission electrocardiogram in low-risk patients hospitalized for COVID-19. <i>Minerva Medica</i> , 2022, 113, .	0.3	4
4	Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 27.	0.8	14
5	Pathophysiology and mechanisms of Acute Coronary Syndromes: atherothrombosis, immune-inflammation, and beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 351-362.	0.6	4
6	Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the Euro Bifurcation Club registry. <i>Panminerva Medica</i> , 2022, , .	0.2	1
7	COVID-19 vaccine-induced immune thrombotic thrombocytopenia. <i>Atherothrombosis</i> , 2022, 12, 114-126.	0.1	0
8	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	1.0	21
9	Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. <i>Vascular Pharmacology</i> , 2021, 137, 106822.	1.0	10
10	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021, 327, 176-182.	0.8	10
11	Accuracy of global and regional longitudinal strain at peak of dobutamine stress echocardiography to detect significant coronary artery disease. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1321-1331.	0.7	7
12	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.	1.0	9
13	Impact of drug-eluting stents on left ventricular wall motion after successful reperfusion of first anterior ST elevation myocardial infarction. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 144-153.	0.4	2
14	Anorexia nervosaâ€related cardiopathy in children with physical instability: prevalence, echocardiographic characteristics and reversibility at mid-term follow-up. <i>European Journal of Pediatrics</i> , 2021, 180, 3379-3389.	1.3	4
15	Predictors of adherence to composite therapy after acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 645-651.	0.6	3
16	Clinical use of cangrelor: a real world multicenter experience from South Italy Insights from the M.O.Ca. registry. <i>Panminerva Medica</i> , 2021, , .	0.2	3
17	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	0.8	35
18	652â€Myocardial work in patients undergoing transcatheter aortic valve implantation: clinical value and implications for outcome. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
19	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
20	Oxidized low-density lipoproteins induce tissue factor expression in T-lymphocytes via activation of lectin-like oxidized low-density lipoprotein receptor-1. <i>Cardiovascular Research</i> , 2020, 116, 1125-1135.	1.8	15
21	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. <i>Angiology</i> , 2020, 71, 235-241.	0.8	3
22	P753 Impact of transcatheter aortic valve implantation on concomitant mitral regurgitation in patients with severe aortic stenosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, .	0.5	0
23	Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF- κ B pathway.. <i>European Journal of Pharmacology</i> , 2020, 885, 173422.	1.7	17
24	Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 660-666.	0.6	10
25	Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 173-180.	0.8	31
26	Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience. <i>Coronary Artery Disease</i> , 2020, 31, 27-34.	0.3	0
27	Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 468-472.	1.0	20
28	Antiplatelet Therapy in Acute Coronary Syndromes. Lights and Shadows of Platelet Function Tests to Guide the Best Therapeutic Approach. <i>Current Vascular Pharmacology</i> , 2020, 18, 262-272.	0.8	13
29	Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. <i>Current Vascular Pharmacology</i> , 2020, 18, 294-301.	0.8	8
30	Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome. Prevention of venous thromboembolism in patients with COVID-19. <i>International Professional Journal Medicine</i> , 2020, 3-4, 2-7.	0.0	1
31	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , 2019, 70, 257-263.	0.8	21
32	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , 2019, 14, e0219676.	1.1	16
33	Human heart shifts from IGF-1 production to utilization with chronic heart failure. <i>Endocrine</i> , 2019, 65, 714-716.	1.1	6
34	How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Postâ€MI Study. <i>Clinical Cardiology</i> , 2019, 42, 1113-1120.	0.7	5
35	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	0.7	20
36	Effects of Hypobaric Hypoxia on Endothelial Function and Adiponectin Levels in Airforce Aviators. <i>High Altitude Medicine and Biology</i> , 2019, 20, 165-170.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Mid-term outcomes after percutaneous interventions in coronary bifurcations. <i>International Journal of Cardiology</i> , 2019, 283, 78-83.	0.8	33
38	Self-expandable sirolimus-eluting stents compared to second-generation drug-eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILSAFE registries. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 208-215.	0.7	1
39	True double bifurcation lesions: new application of the self-expandable Axxess stent and review of literature with dedicated bifurcation devices. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 254-260.	0.3	3
40	Comparison of the Effect of Dual-Axis Rotational Coronary Angiography Versus Conventional Coronary Angiography on Frequency of Acute Kidney Injury, X-Ray Exposure Time, and Quantity of Contrast Medium Injected. <i>American Journal of Cardiology</i> , 2018, 121, 1046-1050.	0.7	6
41	Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. <i>American Journal of Cardiology</i> , 2018, 122, 6-11.	0.7	13
42	Relationship between Pregnancy-associated Plasma Protein-A and tissue factor levels in the coronary circulation of patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2018, 258, 14-16.	0.8	4
43	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , 2018, 69, 795-802.	0.8	35
44	Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. <i>Angiology</i> , 2018, 69, 103-112.	0.8	8
45	P5581 Self-expandable sirolimus-eluting stents for the treatment of the unprotected left main: propensity score-matched comparison with second generation drug-eluting stents. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
46	P3171 Impact of untreated coronary artery disease after primary percutaneous coronary intervention on two years clinical outcome: the residual added index. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
47	4058 Effects of selective and nonselective beta-blockers on platelet aggregation in patients with acute coronary syndrome: the PLATE-BLOCK study. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
48	P6358 Comparison of residual added index with residual SYNTAX score in the risk stratification of patients with incomplete coronary percutaneous revascularization after ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
49	Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 581-593.	0.7	43
50	Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. <i>Vascular Pharmacology</i> , 2018, 111, 62-70.	1.0	38
51	Lights and shadows of long-term dual antiplatelet therapy in â€œreal lifeâ€œ-clinical scenarios. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 559-569.	1.0	1
52	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2018, 122, 936-943.	0.7	12
53	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. <i>International Journal of Cardiology</i> , 2018, 273, 8-14.	0.8	18
54	Nobiletin inhibits oxidized-LDL mediated expression of Tissue Factor in human endothelial cells through inhibition of NF-Î²B. <i>Biochemical Pharmacology</i> , 2017, 128, 26-33.	2.0	23

#	ARTICLE	IF	CITATIONS
55	Abluminal-Coated Drug-Eluting Bifurcation-Dedicated Stent for the Treatment of Tibioperoneal Bifurcation. <i>Vascular and Endovascular Surgery</i> , 2017, 51, 327-330.	0.3	1
56	Antiplatelet Therapy for Non-â€œST-Segment Elevation Myocardial Infarction in Complex â€œReal-â€œClinical Scenarios: A Consensus Document of the â€œCampania NSTEMI Study Groupâ€œ. <i>Angiology</i> , 2017, 68, 598-607.	0.8	1
57	Meta-Analysis of Effect of Body Mass Index on Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2017, 119, 308-316.	0.7	37
58	From Femoral to Radial Approach in Coronary Intervention. <i>Angiology</i> , 2017, 68, 281-287.	0.8	21
59	Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque. <i>Current Cardiology Reviews</i> , 2017, 13, 110-117.	0.6	31
60	Upregulation of TH/IL-17 Pathway-Related Genes in Human Coronary Endothelial Cells Stimulated with Serum of Patients with Acute Coronary Syndromes. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 1.	1.1	28
61	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <i>PLoS ONE</i> , 2017, 12, e0186961.	1.1	21
62	Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches. <i>Current Vascular Pharmacology</i> , 2017, 15, 197-206.	0.8	6
63	Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target. <i>Current Vascular Pharmacology</i> , 2017, 15, 404-415.	0.8	28
64	Very late bioresorbable scaffold thrombosis and reoccurrence of dissection two years later chronic total occlusion recanalization of the left anterior descending artery. <i>World Journal of Cardiology</i> , 2017, 9, 710.	0.5	0
65	Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt-â€œNF-â€œB axis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 225-232.	1.0	13
66	Quantitative detection of inducible ischemia during dobutamine stress by speckle tracking echocardiography: A dream comes true. <i>International Journal of Cardiology</i> , 2016, 220, 357-359.	0.8	7
67	Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8-Åyears follow up study. <i>Cardiovascular Diabetology</i> , 2016, 15, 147.	2.7	6
68	Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo : A possible contribution of immunity to thrombosis?. <i>International Journal of Cardiology</i> , 2016, 218, 188-195.	0.8	24
69	The adipokine apelin-13 induces expression of prothrombotic tissue factor. <i>Thrombosis and Haemostasis</i> , 2015, 113, 363-372.	1.8	18
70	Fructose induces prothrombotic phenotype in human endothelial cells. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 444-451.	1.0	12
71	Diastolic dysfunction reduces stroke volume during daily's life activities in patients with severe aortic stenosis. <i>International Journal of Cardiology</i> , 2015, 195, 64-65.	0.8	2
72	Activating stimuli induce platelet microRNA modulation and proteome reorganisation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 96-108.	1.8	40

#	ARTICLE	IF	CITATIONS
73	Multiple composite grafts (k, Y or double-Y) in coronary artery surgery: a choice or a necessity?. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 60-66.	0.5	5
74	Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor. Journal of Thrombosis and Thrombolysis, 2015, 40, 186-192.	1.0	19
75	Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry. Cardiovascular Revascularization Medicine, 2015, 16, 401-405.	0.3	2
76	Adipokines, Vascular Wall, and Cardiovascular Disease. Angiology, 2015, 66, 8-24.	0.8	23
77	Pharmacotherapeutic Considerations for the Use of Prasugrel and Ticagrelor to Reduce Stent Thrombosis in Patients With Acute Coronary Syndrome. Angiology, 2014, 65, 130-136.	0.8	10
78	Meta-Analysis of Mortality Outcomes and Mitral Regurgitation Evolution in 4,839 Patients Having Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. American Journal of Cardiology, 2014, 114, 875-882.	0.7	60
79	The pitfalls of managing thrombosis of an Absorbâ„¢-treated bifurcation. International Journal of Cardiology, 2014, 174, e93-e95.	0.8	2
80	Reperfusion Correlates and Clinical Outcomes of Right Ventricular Dysfunction in Patients With Inferior ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 114, 243-249.	0.7	11
81	Local cytokine production in patients with Acute Coronary Syndromes: A look into the eye of the perfect (cytokine) storm. International Journal of Cardiology, 2014, 176, 227-229.	0.8	13
82	No-Reflow Phenomenon. Angiology, 2014, 65, 180-189.	0.8	63
83	C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. International Journal of Cardiology, 2013, 168, 981-986.	0.8	46
84	Cardiovascular Disease and High-Mobility Group Box 1 "Is a New Inflammatory Killer in Town?. Angiology, 2013, 64, 343-355.	0.8	7
85	Î²₁-Adrenergic Receptor and Sphingosine-1-Phosphate Receptor 1 (S1PR1) Reciprocal Downregulation Influences Cardiac Hypertrophic Response and Progression to Heart Failure. Circulation, 2013, 128, 1612-1622.	1.6	69
86	Multi-slice computed tomography assessment of stent position in a patient with acute coronary syndrome and anomalous origin of the coronary arteries : online article - case report. Cardiovascular Journal of Africa, 2013, 24, e1-e3.	0.2	0
87	Adipose tissue in the pathophysiology of cardiovascular disease: Who is guilty?. World Journal of Hypertension, 2012, 2, 13.	0.8	0
88	The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells. Thrombosis Research, 2012, 130, 403-408.	0.8	19
89	MGUard versus bAreâ€metal stents plus manual thRombectomy in STâ€elevation myocarDial infarction pAtieNtsâ€ (GUARDIAN) trial: Study design and rationale. Catheterization and Cardiovascular Interventions, 2012, 79, 1118-1126.	0.7	18
90	Effects of Exercise Training on High-Mobility Group Box-1 Levels After Acute Myocardial Infarction. Journal of Cardiac Failure, 2011, 17, 108-114.	0.7	41

#	ARTICLE	IF	CITATIONS
91	A new approach to percutaneous coronary revascularization in patients requiring undeferrable non-cardiac surgery. <i>International Journal of Cardiology</i> , 2011, 146, 399-403.	0.8	17
92	Transcoronary Th-17 lymphocytes and acute coronary syndromes: new evidence from the crime scene?. <i>International Journal of Cardiology</i> , 2011, 153, 215-216.	0.8	11
93	Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology. <i>Current Vascular Pharmacology</i> , 2011, 9, 188-199.	0.8	52
94	Percutaneous coronary intervention in a patient with acute non-ST-elevation myocardial infarction and haemophilia A: a â€˜genous</i>â€™ experience. <i>Haemophilia</i> , 2011, 17, e245-6.	1.0	13
95	Acquired left coronary artery fistula draining to the cardiac vein system after acute myocardial infarction revealed by CT scan. <i>Clinical Imaging</i> , 2011, 35, 395-397.	0.8	1
96	Treatment of Residual Type A Aortic Dissection With Implantation of the Djumbodis System: Is Purely Endovascular Treatment Becoming a Reality?. <i>Journal of Endovascular Therapy</i> , 2011, 18, 368-373.	0.8	11
97	Tissue Factor Is Induced by Resistin in Human Coronary Artery Endothelial Cells by the NF- κ B-Dependent Pathway. <i>Journal of Vascular Research</i> , 2011, 48, 59-66.	0.6	58
98	Endovascular treatment of residual type A aortic dissection preserving patency of supra-aortic vessels by implantation of the Djumbodis [®] system. No more surgery for the aortic arch?. <i>Journal of Invasive Cardiology</i> , 2011, 23, E251-3.	0.4	1
99	Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?. <i>Current Vascular Pharmacology</i> , 2010, 8, 259-275.	0.8	58
100	Successful use of the Cardiva Boomerang [®] , ϕ vascular closure device to close a brachial artery puncture site after emergency PTCA. <i>Heart and Vessels</i> , 2010, 25, 565-568.	0.5	9
101	Multicentre experience with MGuard [®] , ϕ net protective stent in ST-elevation myocardial infarction: Safety, feasibility, and impact on myocardial reperfusion. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 715-721.	0.7	31
102	Pro-atherothrombotic effects of leptin in human coronary endothelial cells. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1065-1075.	1.8	41
103	Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 208, 280-284.	0.4	30
104	Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?. <i>Current Cardiology Reviews</i> , 2010, 6, 325-332.	0.6	8
105	Leptin Stimulated C-Reactive Protein Production by Human Coronary Artery Endothelial Cells. <i>Journal of Vascular Research</i> , 2009, 46, 609-617.	0.6	51
106	Different vascular response to concurrent implantation of sirolimus- and zotarolimus-eluting stents in the same vessel. <i>Heart and Vessels</i> , 2009, 24, 313-316.	0.5	6
107	Increased High Mobility Group Box-1 Protein Levels are Associated With Impaired Cardiopulmonary and Echocardiographic Findings After Acute Myocardial Infarction. <i>Journal of Cardiac Failure</i> , 2009, 15, 362-367.	0.7	39
108	Latent left ventricular outflow tract obstruction induced by abnormal hypertrophic papillary muscle caused myocardial ischemia. <i>International Journal of Cardiology</i> , 2009, 132, 270-272.	0.8	4

#	ARTICLE	IF	CITATIONS
109	Effects of exercise-based cardiac rehabilitation on high mobility group box-1 levels after acute myocardial infarction: rationale and design. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 659-663.	0.6	9
110	Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 726-736.	1.9	34
111	Abciximab in elderly with Acute Coronary Syndrome invasively treated: Effect on outcome. <i>International Journal of Cardiology</i> , 2008, 130, 380-385.	0.8	6
112	In concomitant coronary and peripheral arterial disease, inflammation of the affected limbs predicts coronary artery endothelial dysfunction. <i>Atherosclerosis</i> , 2008, 201, 440-446.	0.4	33
113	Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 113-118.	3.1	79
114	Insights into pathophysiology of smoke-related cardiovascular disease. <i>Monaldi Archives for Chest Disease</i> , 2008, 70, 59-67.	0.3	2
115	HMG-CoA Reductase Inhibitors Reduce Nicotine-Induced Expression of Cellular Adhesion Molecules in Cultured Human Coronary Endothelial Cells. <i>Journal of Vascular Research</i> , 2007, 44, 460-470.	0.6	25
116	Rheolytic Thrombectomy during Percutaneous Coronary Intervention Improves Long-Term Outcome in High-Risk Patients with Acute Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2007, 20, 292-298.	0.5	22
117	Nicotine induces tissue factor expression in cultured endothelial and smooth muscle cells. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 453-458.	1.9	31
118	Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2248-2255.	1.9	39
119	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. <i>Cardiovascular Research</i> , 2005, 68, 47-55.	1.8	126
120	Role of β_2 Adrenergic Receptors in Human Atherosclerotic Coronary Arteries. <i>Circulation</i> , 2005, 111, 288-294.	1.6	68
121	Tissue Factor Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal-Regulated Kinase Activation. <i>Circulation</i> , 2004, 109, 2911-2916.	1.6	63
122	Estimation of coronary flow reserve by Tc-99m sestamibi imaging in patients with coronary artery disease: Comparison with the results of intracoronary Doppler technique. <i>Journal of Nuclear Cardiology</i> , 2004, 11, 682-688.	1.4	48
123	Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 992-998.	1.9	11
124	Activated platelets stimulate tissue factor expression in smooth muscle cells. <i>Thrombosis Research</i> , 2003, 112, 51-57.	0.8	23
125	Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 108, 2864-2869.	1.6	41
126	Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1684-1689.	1.1	8

#	ARTICLE	IF	CITATIONS
127	Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. <i>Journal of the American College of Cardiology</i> , 2001, 38, 569-576.	1.2	37
128	Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, S149-S158.	0.5	10
129	Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 278, H1507-H1516.	1.5	49
130	Endogenous Tissue Factor Pathway Inhibitor Modulates Thrombus Formation in an In Vivo Model of Rabbit Carotid Artery Stenosis and Endothelial Injury. <i>Circulation</i> , 2000, 102, 113-117.	1.6	46
131	Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. <i>Cardiovascular Research</i> , 1999, 43, 210-218.	1.8	43
132	A Simple Method for the Isolation, Cultivation, and Characterization of Endothelial Cells from Rabbit Coronary Circulation. <i>Thrombosis Research</i> , 1999, 96, 329-333.	0.8	11
133	A Short Burst of Oxygen Radicals at Reflow Induces Sustained Release of Oxidized Glutathione from Postischemic Hearts. <i>Free Radical Biology and Medicine</i> , 1998, 24, 290-297.	1.3	40
134	Antithrombotic Effects of Recombinant Human, Active Site-Blocked Factor VIIa in a Rabbit Model of Recurrent Arterial Thrombosis. <i>Circulation Research</i> , 1998, 82, 39-46.	2.0	82
135	Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. <i>Nature Medicine</i> , 1996, 2, 35-40.	15.2	171
136	Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis. <i>Circulation</i> , 1996, 93, 1913-1918.	1.6	59
137	Aurintricarboxylic Acid Reduces Platelet Deposition in Stenosed and Endothelially Injured Rabbit Carotid Arteries more Effectively than other Antiplatelet Interventions. <i>Thrombosis and Haemostasis</i> , 1995, 74, 974-979.	1.8	20
138	Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. <i>Thrombosis and Haemostasis</i> , 1995, 74, 974-9.	1.8	1
139	Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow.. <i>Journal of Biological Chemistry</i> , 1993, 268, 18532-18541.	1.6	471
140	Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. <i>Journal of Biological Chemistry</i> , 1993, 268, 18532-41.	1.6	378
141	Bivalirudin Inhibits Thrombin-Mediated Tissue Factor Expression in Human Endothelial Cells. <i>Journal of Advanced Therapies and Medical Innovation Sciences</i> , 0, 2, .	0.0	0
142	Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. <i>Clinical Cardiology</i> , 0, , .	0.7	5